Associated Papers
Protein Tyrosine Phosphatase Non-Receptor 11 (PTPN11/Shp2) as a Driver Oncogene and a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC).
Richards CE et al.
International Journal of Molecular Sciences, 2023
37445722 (PubMed )
Supplement: ijms-24-10545-s001.zip › PTPN11_paper_supplementary_tables_25042023.pdf
Clinically actionable cancer somatic variants (CACSV): a tumor interpreted dataset for analytical workflows.
Sobahy TM et al.
Bmc Medical Genomics, 2022
35468810 (PubMed )
Supplement: 12920_2022_1235_MOESM2_ESM.xlsx › Sheet1
Molecular Alterations in Thyroid Cancer: From Bench to Clinical Practice.
Tirrò E et al.
Genes, 2019
IDH1-mutated transgenic zebrafish lines: An in-vivo model for drug screening and functional analysis.
Gao Y et al.
Plos One, 2018
Role of isocitrate dehydrogenase 1/2 (IDH 1/2) gene mutations in human tumors.
Liu X et al.
Histology and Histopathology, 2015
IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma.
Zhang C et al.
Neuro-oncology, 2013
IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives.
Yang H et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2012
Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production.
Ward PS et al.
Oncogene, 2012
Identification of several novel non-p.R132 IDH1 variants in thyroid carcinomas.
Hemerly JP et al.
European Journal of Endocrinology, 2010
Select a paper to view details